Affymax, Inc.

Covx Technologies Ireland Limited

Pfizer Healthcare Ireland

David Tumelty

Christopher P Holmes

Qun Yin

Peter J Schatz

Genet Zemede

Guy Lalonde

Balu Palani

Palani Balu

Abhijit Suresh Bhat

Alice Lee

Olivier Alexandre Laurent

Wei Hong Yu

Richard Ryan Preston

Curt William Bradshaw

Anna Maria Tempczyk-Russell

Paul Van Slyke

Kevin Yin

Jason Moss

Lauren Diane Wood

Anna Tempczyk-russell

Daniel (deceased) Dumont

Kenneth Sokoll

Chris Holmes

The present invention relates to a polypeptide comprising 7 &#x3b2;-strands A, B, C, D, E, F, and G sequentially connected together by connecting chains of amino acids, and a first &#x3b1;-helix sequentially located on the EF chain between &#x3b2;-strands E and F, wherein the &#x3b2;-strands are arranged so as to form a first &#x3b2;-sheet comprising &#x3b2;-strands A, B, D, and E, and a second &#x3b2;-sheet comprising &#x3b2;-strands C, F and G, said first and second &#x3b2;-sheets being covalently bonded together so as to form a first Ig domain; wherein the EF chain between &#x3b2;-strands E and F comprises the sequence X-X-X-X-KH(SEQ ID NO:98), and X, Xand Xare each independently any amino acid residue, characterized in that Xis selected from the group consisting of A, G, I, V, L, R, S, T, Q, P, N, M, H, W, and pharmaceutically acceptable salts, stereoisomers, tautomers, solvates, and prodrugs thereof.

Mutant antibodies and conjugation thereof

The present invention relates to Multifunctional Antibody Conjugates, comprising an antibody or antigen binding portion thereof, comprising at least a fragment of a light chain constant kappa region (CL&#x3ba;) comprising Kaccording to Kabat numbering; a linker comprising the formula X-Y-Z, wherein Z is a group is covalently connected to the antibody through the side chain of K, Y is a linear or branched biologically compatible connecting chain, and X is a group covalently connected to at least one Effector Moiety. The invention further provides specific MAC compounds and compositions of the invention.

Multifunctional antibody conjugates

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Peptides that bind to the erythropoietin receptor

The present invention relates to a compound comprising a peptide moiety, a spacer moiety and a water-soluble polymer moiety such as a poly(ethylene glycol) moiety. The spacer moiety is between the peptide moiety and the water-soluble polymer moiety. The spacer moiety has the structure:&#x2014;NH&#x2014;(CH)&#x2014;[O&#x2014;(CH)]&#x2014;O&#x2014;(CH)&#x2014;Y&#x2014;wherein &#x3b1;, &#x3b2;, &#x3b3;, &#x3b4;, and &#x3b5; are each integers whose values are independently selected.

Spacer moiety for poly(ethylene glycol) modified peptide based compounds

Peptide compounds that are agonists of the erythropoietin receptor (EPO-R) are described, as well as therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Spacer moiety for poly (ethylene glycol) modified peptide based compounds

Growing community of inventors

Sunnyvale, CA, United States of America

David Tumelty